These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12394330)

  • 1. Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma--a 2-year follow-up study.
    Nilsson TK; Spence JD; Nilsson PM; Eliasson M; Jansson JH; Boman K
    J Cardiovasc Risk; 2002 Aug; 9(4):215-21. PubMed ID: 12394330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
    Wiman B; Andersson T; Hallqvist J; Reuterwall C; Ahlbom A; deFaire U
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):2019-23. PubMed ID: 10938026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.
    Wållberg-Jonsson S; Dahlén GH; Nilsson TK; Rånby M; Rantapää-Dahlqvist S
    Clin Rheumatol; 1993 Sep; 12(3):318-24. PubMed ID: 8258230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure--a COMET substudy.
    Boman K; Jansson JH; Nilsson T; Swedberg K; Cleland JG; Poole-Wilson P
    Thromb Res; 2010 Feb; 125(2):e46-50. PubMed ID: 19762071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.
    Thögersen AM; Jansson JH; Boman K; Nilsson TK; Weinehall L; Huhtasaari F; Hallmans G
    Circulation; 1998 Nov; 98(21):2241-7. PubMed ID: 9826309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
    Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
    Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase.
    Nilsson JB; Boman K; Jansson JH; Nilsson T; Näslund U
    J Thromb Thrombolysis; 2008 Dec; 26(3):188-95. PubMed ID: 17721741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
    Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG
    Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment.
    Brännström M; Jansson JH; Boman K; Nilsson TK
    Thromb Haemost; 1995 Aug; 74(2):612-5. PubMed ID: 8584993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the association of elevated tPA/PAI-1 complex and von Willebrand factor with recurrent myocardial infarction.
    Bounameaux H; Kruithof EK
    Arterioscler Thromb Vasc Biol; 2000 Aug; 20(8):1857-9. PubMed ID: 10938004
    [No Abstract]   [Full Text] [Related]  

  • 11. Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study.
    Hernestål-Boman J; Norberg M; Jansson JH; Eliasson M; Eriksson JW; Lindahl B; Johansson L
    Cardiovasc Diabetol; 2012 Dec; 11():152. PubMed ID: 23249721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.
    Tofler GH; Massaro J; O'Donnell CJ; Wilson PWF; Vasan RS; Sutherland PA; Meigs JB; Levy D; D'Agostino RB
    Thromb Res; 2016 Apr; 140():30-35. PubMed ID: 26896607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction.
    Jansson JH; Nilsson TK; Johnson O
    Heart; 1998 Oct; 80(4):334-7. PubMed ID: 9875107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelial dysfunction and systemic inflammation in persons with echolucent carotid plaques.
    With Notø AT; Bøgeberg Mathiesen E; Amiral J; Vissac AM; Hansen JB
    Thromb Haemost; 2006 Jul; 96(1):53-9. PubMed ID: 16807651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology.
    Zunker P; Schick A; Padró T; Kienast J; Phillips A; Ringelstein EB
    Neurol Res; 1999 Dec; 21(8):727-32. PubMed ID: 10596380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients.
    Bicakcigil M; Tasan D; Tasdelen N; Mutlu N; Yavuz S
    Lupus; 2011 Oct; 20(10):1063-71. PubMed ID: 21719525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years.
    Thøgersen AM; Nilsson TK; Weinehall L; Boman K; Eliasson M; Hallmans G; Jansson JH
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):340-6. PubMed ID: 19357504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
    De Pergola G; De Mitrio V; Sciaraffia M; Pannacciulli N; Minenna A; Giorgino F; Petronelli M; Laudadio E; Giorgino R
    Metabolism; 1997 Nov; 46(11):1287-93. PubMed ID: 9361687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Von Willebrand factor antigen levels predict major adverse cardiovascular events in patients with carotid stenosis of the ICARAS study.
    Kovacevic KD; Mayer FJ; Jilma B; Buchtele N; Obermayer G; Binder CJ; Blann AD; Minar E; Schillinger M; Hoke M
    Atherosclerosis; 2019 Nov; 290():31-36. PubMed ID: 31557676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction.
    Thøgersen AM; Söderberg S; Jansson JH; Dahlén G; Boman K; Nilsson TK; Lindahl B; Weinehall L; Stenlund H; Lundberg V; Johnson O; Ahrén B; Hallmans G
    Eur J Cardiovasc Prev Rehabil; 2004 Feb; 11(1):33-40. PubMed ID: 15167204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.